NEW YORK, Nov. 23 - Abbott Laboratories' $355 million acquisition of Vysis came one step closer to closing on Friday as the Hart-Scott- Rodino Antitrust Improvements Act waiting period expired.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: genetic link between birth weight and adult-onset diseases, and more.
Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.
DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.
Researchers discuss the need for antibody standards at a meeting, NPR reports.